|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-4-4
|
|
pubmed:abstractText |
Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer. We investigated the association between grade 3 HFS and genetic variations in genes involved in capecitabine metabolism.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AlonsoMaria RMR,
pubmed-author:BenítezJavierJ,
pubmed-author:CaroniaDanielaD,
pubmed-author:Díaz-RubioEduardoE,
pubmed-author:García-SáenzJosé AngelJA,
pubmed-author:González-NeiraAnnaA,
pubmed-author:MartinMiguelM,
pubmed-author:MorenoLeticia TLT,
pubmed-author:PitaGuillermoG,
pubmed-author:SastreJavierJ,
pubmed-author:de la TorreJulioJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2006-13
|
|
pubmed:meshHeading |
pubmed-meshheading:21325291-Adult,
pubmed-meshheading:21325291-Aged,
pubmed-meshheading:21325291-Aged, 80 and over,
pubmed-meshheading:21325291-Antimetabolites, Antineoplastic,
pubmed-meshheading:21325291-Base Sequence,
pubmed-meshheading:21325291-Binding Sites,
pubmed-meshheading:21325291-Breast Neoplasms,
pubmed-meshheading:21325291-Cell Line, Tumor,
pubmed-meshheading:21325291-Colorectal Neoplasms,
pubmed-meshheading:21325291-Cytidine Deaminase,
pubmed-meshheading:21325291-Deoxycytidine,
pubmed-meshheading:21325291-E2F Transcription Factors,
pubmed-meshheading:21325291-Erythema,
pubmed-meshheading:21325291-Female,
pubmed-meshheading:21325291-Fluorouracil,
pubmed-meshheading:21325291-Foot Dermatoses,
pubmed-meshheading:21325291-Genetic Association Studies,
pubmed-meshheading:21325291-Genetic Predisposition to Disease,
pubmed-meshheading:21325291-Hand Dermatoses,
pubmed-meshheading:21325291-Haplotypes,
pubmed-meshheading:21325291-Humans,
pubmed-meshheading:21325291-Logistic Models,
pubmed-meshheading:21325291-Male,
pubmed-meshheading:21325291-Middle Aged,
pubmed-meshheading:21325291-Pain,
pubmed-meshheading:21325291-Polymorphism, Single Nucleotide,
pubmed-meshheading:21325291-Prodrugs,
pubmed-meshheading:21325291-Promoter Regions, Genetic,
pubmed-meshheading:21325291-Sequence Analysis, DNA,
pubmed-meshheading:21325291-Syndrome,
pubmed-meshheading:21325291-Transcription, Genetic
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
|
|
pubmed:affiliation |
Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
